Bristol-Myers Squibb

This phase 2 trial is testing whether an experimental drug called BMS-986511 can reduce symptoms of major depressive disorder in adults. Participants with moderate to severe depression will receive either the drug or a placebo, and researchers will track changes in depression sco…

This trial gives deucravacitinib, an oral drug that calms the immune system, to adults with lupus or Sjögren's disease and to children with psoriasis or psoriatic arthritis. Participants join after finishing an earlier study of the same drug, and the goal is to see how safe and t…

This phase 3 trial tests whether adding an experimental drug called izalontamab brengitecan to the standard targeted therapy osimertinib works better than osimertinib alone or with chemotherapy for people with advanced EGFR-mutant non-small cell lung cancer who have not had prior…

This early-stage trial evaluates an investigational drug called BMS-986446 (moponetug) in healthy adults and in people with early Alzheimer's disease. The study aims to understand how the drug moves through the body, its safety, and how well it is tolerated when given as a single…

This study looks at the long-term safety of a drug called admilparant in people with pulmonary fibrosis (lung scarring). About 2,277 adults who finished earlier studies will take the drug and be monitored for side effects. The goal is to see if the drug is safe to use over time, …

This study tests a combination of two immunotherapy drugs, nivolumab and relatlimab, in people with advanced melanoma that hasn't been treated before. The goal is to see if the combination is safe and helps shrink tumors. About 30 adults and teens (ages 12 and up) in India will t…

This study looks at whether luspatercept, a drug given as first-line treatment, can help adults with low-risk myelodysplastic neoplasms (MDS) who need regular red blood cell transfusions. Researchers will follow about 190 participants for up to 2 years to see how often they achie…

This Phase 3 study tests whether a combination of two drugs, KarXT and KarX-EC, can safely reduce irritability in children and adolescents aged 5 to 17 with autism spectrum disorder. About 176 participants will receive either the drug combo or a placebo for 8 weeks. The main goal…

This study tests whether a new medication, KarXT + KarX-EC, can reduce irritability in children and teens (ages 5 to 17) with autism. About 176 participants will receive either the drug or a placebo. The main goal is to see if the drug improves irritability scores after 8 weeks.

This phase 1 trial enrolls healthy adult women to measure how an experimental drug called navlimetostat behaves when taken with a high-fat meal or with other medications like itraconazole, rifampin, midazolam, and pantoprazole. Researchers will track drug levels in the blood and …

This phase 1 study aims to understand how the body processes and eliminates navlimetostat (BMS-986504), an experimental drug. A small group of healthy female volunteers will receive a specially labeled version of the drug that can be tracked in blood, urine, and feces. By measuri…

This study looks at how the experimental drug golcadomide is processed by the body in people with severe kidney impairment or end-stage renal disease compared to those with normal kidney function. The goal is to understand how kidney function affects drug levels and safety after …

This study uses web-based interviews to explore how adults in Japan with pulmonary fibrosis decide whether to continue or stop antifibrotic therapy after experiencing side effects. Researchers aim to understand the personal and psychological factors behind these decisions. The fi…

This study watches how well the drug repotrectinib works and what side effects it causes in Korean patients with a specific type of lung cancer or solid tumors that have certain gene changes. About 10 patients will be followed for up to 12 months during their normal treatment. Th…

This study is a registry that will collect information from about 500 adults in Asia who have been diagnosed with myelodysplastic syndromes (MDS). Researchers will look at patient details like age, sex, medical history, lab results, and treatments received. The goal is to better …